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 Abstract  
Objective: To examine the effects of topically applied recombinant human insulin-like 
growth factor 1 (IGF1) via gelatin hydrogels on alterations in pure-tone audiometry 
(PTA) in patients with sudden sensorineural hearing loss (SSHL) refractory to systemic 
steroids. 
Study Design: Retrospective chart review. Setting: A single University Hospital. 
Patients: Twenty-five patients with SSHL refractory to systemic steroids who received 
topical IGF1 treatment.  
Intervention: Single topical application of IGF1 to the round window niche using 
gelatin hydrogels. 
Main Outcome Measures: The primary outcome was alterations in PTA thresholds at 
frequencies of 0.25, 0.5, 1, 2 and 4 kHz following topical IGF1 application. Secondary 
outcomes included differences in final improvements in PTA thresholds among 
frequencies tested and cumulative numbers of patients showing 10- or 20-dB recovery 
in PTA during the observation period. 
Results: Topical IGF1 application via gelatin hydrogels significantly altered PTA 
thresholds at each frequency tested and at the average frequency. The numbers of 
patients with a 10-dB recovery in PTA increased until four weeks after treatment and 
then stabilized, while those patients showing 20-dB recovery gradually increased during 
the observation period. 
Conclusions: Topical IGF1 application via gelatin hydrogels contributes to the recovery 
of PTA levels in patients with SSHL refractory to systemic steroids. Major recovery of 
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Sudden sensorineural hearing loss (SSHL) is the most common cause of acute 
sensorineural hearing loss and is one of the few types that can be cured, with 
spontaneous recovery occurring in 30–60% of  cases (1, 2). Most recoveries occur 
within the first two weeks of onset, and, after this time, it can be difficult to detect 
further improvement in hearing. The most common therapy for SSHL is the systemic 
application of glucocorticoids (3, 4), but about 20% of patients do not respond to this 
treatment (5). In addition, no therapy has been demonstrated to be effective according to 
the evidence criteria (6).  
   Various experimental studies have been performed to identify alternative 
therapeutics for acute sensorineural hearing loss including SSHL, and, of several 
potential candidates, insulin-like growth factor 1 (IGF1) was shown to be crucial for the 
development and maintenance of the cochlea (7); its clinical use has also been permitted, 
so it is a reasonable treatment for us to focus on. IGF1 delivery to the cochlear fluid at 
appropriate concentrations for sufficient durations has proved difficult, however, as 
most drugs, particularly growth factors, require sustained delivery for their appropriate 
actions. Topical application can increase drug concentrations in the cochlear fluid, but 
simple tympanic injection does not achieve sustained delivery (8). To overcome this, we 
have utilized gelatin hydrogels for the sustained release of proteins or peptides in topical 
cochlear treatment (9, 10).  
   Based on our pre-clinical studies (11-13), we performed a prospective clinical trial 
to test the safety and efficacy of topical IGF1 application via gelatin hydrogels for 
SSHL refractory to systemic steroids (14). The main outcome measures of this clinical 
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trial were the proportions of patients showing hearing improvement, as determined by 
hearing recovery of 10-dB or above in the mean level of five frequencies tested in 
pure-tone audiometry (PTA) at 12 and 24 weeks after the test treatment. The null 
hypothesis was that 33% of patients would show hearing improvement, as was reported 
for a historical control after hyperbaric oxygen therapy (15). At 12 weeks after treatment, 
48% of patients showed hearing improvement, and this proportion increased to 56% at 
24 weeks, which was statistically significant (14). These findings indicate that topical 
IGF1 application may be efficacious for hearing recovery in patients with SSHL 
refractory to systemic steroids. However, details of audiometric alterations following 
topical IGF1 treatment have not yet been elucidated, and might prove crucial for 
understanding mechanisms of IGF1 therapeutic effects on SSHL and for the design of a 
consecutive randomized trial. The present study therefore aimed to understand these 




MATERIALS AND METHODS 
Patients 
Medical records were reviewed of 25 patients (13 females and 12 males, of median age 
49 years at registration [range, 23–72 years]) with SSHL who received topical IGF1 
treatment in our previous clinical trial (14). Briefly, the main inclusion criteria of our 
previous clinical trial were as follows: diagnosis of SSHL within 29 days of onset at the 
Department of Otolaryngology, Head and Neck Surgery of Kyoto University Hospital, 
Kyoto, Japan, and hearing recovery of less than 10-dB for an average of PTA thresholds 
at five frequencies (0.25, 0.5, 1, 2 and 4 kHz) after systemic steroid treatment. We 
excluded patients with active chronic otitis media, acute otitis media, otitis media with 
effusion or dysfunction of the auditory tube, malignant tumors, severe liver dysfunction 
(aspartate aminotransferase [AST] >100 and alanine aminotransferase [ALT] >100), 
uncontrolled diabetes (haemoglobin A1C [HbA1c] >10), pituitary or adrenal 
dysfunction, severe systemic illness that affected life expectancy, a history of severe 
drug allergy, or a history of alcohol or drug dependence within the past 1 year, and 
pregnant or lactating women. All patients registered in this study had no previous 
history of noise exposure. This study was conducted in accordance with the Declaration 
of Helsinki and its amendments, and approved by the Ethical Committee of the 
Graduate School of Medicine, Kyoto University (registered number, C165). Each 
patient gave written, informed consent to participate in this study. 
 
Intervention  
Patients received topical IGF1 treatment using gelatin hydrogels at a median of 23 days 
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(range 15–32 days) after the onset of SSHL, between 2007 and 2009 at Kyoto 
University Hospital. Gelatin hydrogels were made from porcine skin gelatin (Nitta 
Gelatin Inc., Osaka, Japan) in a clean room at the Department of Pharmacy, Kyoto 
University Hospital. Topical IGF1 treatment procedures were performed in the 
Day-Surgery Unit of Kyoto University Hospital. Mecasermin (recombinant human 
IGF1, Somazon®, 10 mg for injection; Astellas Pharma Inc., Tokyo, Japan) was 
dissolved in physiological saline at a final concentration of 10 mg/ml. A 30-µl sample of 
mecasermin solution was mixed with 3 mg gelatin hydrogels 60 min before application. 
The single treatment involved placing hydrogel containing 300 µg  mecasermin in the 
round-window niche of the middle ear following tympanostomy under local anesthesia 
with 1% lidocaine. Patients were hospitalized for four days after the surgical procedure, 
and their general and local conditions were examined at the outpatient clinic of the 
Department of Otolaryngology, Head and Neck Surgery, Kyoto University Hospital, for 
24 weeks after the test treatment.  
 
Audiometric examination 
PTA was performed on the day of registration and at one, two, four, 12 and 24 weeks 
after the test treatment. Thresholds in air-conductance at frequencies of 0.25, 0.5, 1, 2, 
and 4 kHz were determined.    
 
Outcome measures 
A retrospective chart review was performed with a primary outcome measure of 
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alterations in PTA thresholds for each frequency tested and for the average of five 
frequencies during the observation period. Secondary outcome measures included 
differences in final improvements of PTA thresholds among frequencies tested, and 
cumulative numbers of patients showing 10- or 20-dB recovery in the average of PTA 
thresholds at each time-point following treatment.  
 
Statistical analysis 
Alterations in PTA thresholds during the observation period and differences in final 
improvements of PTA thresholds among frequencies tested were examined by the 
repeated measurement analysis of variance (ANOVA). The final recovery in PTA 
thresholds following topical IGF1 treatment was compared with that in a historical 
control of hyperbaric oxygen therapy for 199 patients with glucocorticoids-resistant 
SSHL in Kyoto University Hospital between October, 2000 and September, 2006 (15) 





Alterations in PTA thresholds 
Figure 1 shows alterations in mean PTA hearing levels between at registration and 24 
weeks after treatment for each patient. The mean PTA hearing level at registration was 
81.2 dB (95% confidence interval [CI], 71.2–91.1) and that of 24 weeks after treatment 
was 69.3 dB (95% CI, 59.8-78.7). The time course of alterations in averages of PTA 
thresholds is shown in Figure 2A and was statistically significant (P < 0.001). Figure 
2B-F shows the time courses of alterations in PTA thresholds at frequencies of 0.25, 0.5, 
1, 2 and 4 kHz, which were all found to be statistically significant (P < 0.001). These 
findings indicate that topical IGF1 treatment via gelatin hydrogels has significant effects 
on the recovery of PTA thresholds in patients with SSHL refractory to systemic steroids. 
 
Difference in PTA recovery among frequencies 
The mean recovery for the average PTA threshold of five frequencies tested 24 weeks 
after treatment was 11.9 dB (95% CI, 5.8–17.9), and means of recoveries in PTA 
thresholds for each frequency are shown in Figure 3. Differences in the recovery of PTA 
thresholds among frequencies were statistically significant (P = 0.0003), and we 
observed a trend that hearing recovery at 2 or 4 kHz was smaller than at lower 
frequencies. These findings indicate that PTA hearing recovery following topical IGF1 
treatment predominantly occurred at low frequencies.  
 
Time-points for hearing recovery 
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Cumulative numbers of patients showing 10- or 20-dB recovery in PTA during the 
observation period are shown in Fig. 4. For the average PTA threshold of five 
frequencies tested, 14 patients showed 10-dB recovery and eight showed 20-dB 
recovery at the end of the observation period. Four weeks after treatment, 10-dB 
recovery was found in 11 patients (79%) and 20-dB recovery in four patients (50%) (Fig. 
4). For each frequency, 10-dB recovery at 4 weeks was found in 17/19 patients (89%) at 
0.25 kHz, 17/19 (89%) at 0.5 kHz, 13/19 (68%) at 1 kHz, 12/14 (86%) at 2 kHz and 
8/12 (67%) at 4 kHz (Fig. 3B-F). At 4 weeks, 20-dB recovery appeared in 7/11 patients 
(64%) at 0.25 kHz, 11/13 (85%) at 0.5 kHz, 7/10 (70%) at 1 kHz, 3/6 (50%) at 2 kHz 
and 5/6 (83%) at 4 kHz. These findings demonstrate that PTA hearing recovery after 
topical IGF1 treatment occurred during the initial four weeks in the majority of patients, 
but that further recovery was evident in some patients at a later stage.  
 
Comparison with a historical control 
The recoveries of PTA thresholds for each frequency tested and for the average of five 
frequencies 24 weeks after topical IGF1 treatment were compared with those in a 
historical control of hyperbaric oxygen therapy (Fig. 3). The recovery of the average 
PTA thresholds after topical IGF1 treatment was larger than that of a historical controls 
(11.9 ± 2.9 [mean ± standard error] for IGF1 v.s. 8.0 ± 0.9 for historical control), 
but the difference was not statistically significant (P = 0.08). For each frequency, there 
is a trend that topical IGF1 treatment shows better PTA threshold recoveries than a 
historical control (Fig. 3). The difference in PTA threshold recoveries at 1 kHz between 
the two group was statistically significant at P = 0.04, while at other frequencies no 
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The present study demonstrates that topical IGF1 treatment has significant effects on the 
PTA thresholds of patients with SSHL refractory to systemic steroids. Topical IGF1 
application using gelatin hydrogels was performed at 23 days after SSHL onset, and led 
to an average recovery of 11.9 dB in PTA thresholds over five frequencies. In 
comparison with a historical control of hyperbaric oxygen therapy, there is a trend that 
topical IGF1 treatment shows better hearing recovery than hyperbaric oxygen therapy, 
and a significant difference in hearing recovery is found at 1 kHz. After topical IGF1 
treatment, recovery at or above 10 dB was found at 0.25, 0.5 and 1 kHz frequencies. 
Maximum recovery of 16.0 dB occurred at 0.5 kHz, while hearing recovery at 2 or 4 
kHz was less than 10 dB, suggesting that irreversible degeneration might occur in the 
high frequency region of cochleae. On the other hand, significant hearing recovery was 
also observed at low frequencies, suggesting that damage in the low frequency region 
may be reversible and respond to IGF1 delivered by gelatin hydrogels from the round 
window.  
Regarding the time course of alterations in PTA thresholds for the average of five 
frequencies, hearing recovery was initiated two weeks after treatment and had stabilized 
by four weeks, which corresponds to recovery starting approximately five weeks after 
the onset of SSHL symptoms and continuing until seven weeks after the onset. In 
general, spontaneous SSHL recovery has been shown to occur between days 3–14 after 
its onset (1, 2), so the PTA recovery observed in the present study may not be 
spontaneous. PTA thresholds at 1 kHz exhibited a trend of linear recovery during the 
observation period, while those at other frequencies and alterations in cumulative 
numbers of patients with a 10 dB recovery showed a similar trend to the average of all 
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five frequencies. An increase in cumulative numbers of patients showing 20 dB 
recovery was slightly delayed in comparison with that showing 10 dB recovery, which 
initiated at four weeks after treatment and continued to 12 weeks. In short, hearing 
recovery following topical IGF1 treatment appeared to take approximately four weeks, 
and, in cases with good recovery, further delayed recovery occurred.  
Previous animal experiments have demonstrated crucial roles of IGF1 in the 
physiolopathology of hearing (16, 17). We have also revealed that IGF1 has 
otoprotective effects against noise- and ischemia-induced cochlear damage using in vivo 
animal models (11-13). As for mechanisms of hearing recovery by IGF1, two possible 
explanations are aroused. One possible mechanism is the rescue of cochlear cells from 
cell death via IGF1 receptor-mediated actions, which has been indicated by animal 
experiments. IGF1 binding to IGF1 receptors activates several intracellular signaling 
pathways associated with the promotion of cell survival (18). Another is the regulation 
of glucose transport in cochlear cells. IGF1 also has insulin-like actions including 
promoting glucose transport (19), which can be associated with the survival of cochlear 
hair cells (20, 21). Both mechanisms might be involved in hearing recovery by topical 
application of IGF1. Further studies are required for elucidation of detailed 
mechanisms.  
Recently, the intratympanic injection of steroids has gained considerable attention as 
an alternative for systemic steroids that may reduce the risk of developing systemic side 
effects and enables the delivery of more steroids into the cochlea. Rauch et al. reported 
that the intratympanic injection of steroid effects as an initial treatment for SSHL are 
not inferior to those of systemic steroids (22), and there is an increasing number of case 
series evaluating intratympanic steroids as a salvage therapy for SSHL refractory to 
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systemic steroids (23-28). Table 1 shows a summary of six studies, of which evidence 
levels are superior to IV, and of which sample sizes are larger than 20 subjects. The 
median PTA recovery obtained in these studies is 14.0 dB (range, 5–22 dB), which is in 
agreement with that obtained in the present study.  
Of previous studies on intratympanic steroids as salvage treatment, two describe 
detailed time courses of PTA thresholds. Ho et al. (29) reported a time course of 
alterations in PTA thresholds following the intratympanic injection of dexamethasone. 
Four weeks after the initiation of treatment (approximately six weeks after the onset), an 
average recovery of 24.3 dB was reported, with little further improvement. Similarly, 
Kilic et al. (26) examined PTA thresholds for an average of four frequencies following 
intratympanic injections of methylprednisolone every three days for a total of five 
applications. At four weeks after the initiation of treatment (approximately eight weeks 
after the onset), an improvement of 19.8 dB was found, with no further improvements 
occurring during the observation period. The time course of hearing recovery after 
topical IGF1 treatment therefore appears to be similar to that which occurs after 
intratympanic steroid application.    
 
Conclusions 
The present results indicate that topical IGF1 application via gelatin hydrogels may be 
efficacious for SSHL refractory to systemic steroids. Although the level and time course 
of hearing recovery following topical IGF1 treatment is similar to that following IT 
steroids, the baselines of PTA thresholds and methods for evaluation vary among studies. 
In addition, pharmacological actions of IGF1 differ from those of steroids. Therefore, 
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the difference in therapeutic potential for SSHL refractory to systemic steroids between 
topical IGF1 and intratympanic steroid treatment is unclear. To clarify this, we are 
currently performing a randomized trial to compare the efficacy of topical IGF1 
treatment with that of intratympanic steroids for SSHL refractory to systemic steroids, 
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Fig. 1. Alterations in hearing levels in pure tone audiometry (PTA) between at 
registration (regist.) and 24 weeks after topical IGF1 treatment in each patients. 
 
Fig. 2. Hearing levels in pure tone audiometry (PTA) at registration (regist.) and 
following topical IGF1 treatment, in the average of five frequencies tested (A), at 0.25 
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kHz (B), 0.5 kHz (C), 1 kHz (D), 2 kHz (E) and 4 kHz (F). Bars represent standard 
errors.  
 
Fig. 3. Final hearing recovery in the average of five frequencies tested and at each 
frequency tested after topical IGF1 treatment or in a historical control of hyperbaric 
oxygen therapy (HBO). An asterisk indicates a significant difference in hearing 
recovery between topical IGF1 treatment and HBO. Bars represent standard errors.  
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 Fig. 4. Cumulative numbers of patients showing 10- or 20-dB recovery in the average of 
five frequencies during the observation period. Bars represent standard errors.  
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 Table 1. Audiometric outcomes in studies of the intratympanic injection of steroids for 
sudden sensorineural hearing loss refractory to systemic steroids. PTA: pure tone 
audiometry, RW: round window, Dex: dexamethasone, Mp: methylprednisolone, NA: 
not available.  
 
First author Sample size Steroid, Dose 
(mg/ml) 
Treatment protocol PTA baseline (dB) Hearing improvement 
(dB) 
Plontke, 2005 [17] 23 Dex (4) or Mp (40) RW microcatheter for 4 
weeks 
103  16 
Choung, 2006 [18] 34 Dex (5) 2 injections/week for 2 
weeks 
72 9 
Roebuck, 2006 [19] 31 Dex (24) 1 injection 69 12 
Kilic, 2007 [20] 20 Mp (62.5 5 injections at 3-day 
intervals 
65 22 
Haynes, 2007 [21] 40 Dex (24) 1 injection NA 5 
Kakehata, 2011 [22] 24 Dex (4)  1 injection/day for 8 days 75 17 
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